University Hospitals of Geneva (HUG)
Welcome,         Profile    Billing    Logout  
 6 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mahipal, Amit
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated
2
3
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells
Adaptimmune, ICON plc
Esophageal Cancer, Esophagogastric Junction Cancer
06/23
12/23
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting
2
122
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
ABOYA-119, NCT04905914: Study of ATRN-119 in Patients with Advanced Solid Tumors

Recruiting
1/2
132
US
ATRN-119
Aprea Therapeutics
Advanced Solid Tumor
12/24
06/25
XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US
XTX301
Xilio Development, Inc.
Advanced Solid Tumor
02/27
02/27
PCS6422-GI-01, NCT04861987: A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

Completed
1
23
US
PCS6422 and capecitabine
Processa Pharmaceuticals
Advanced Cancer, Refractory Cancer, Tumor Gastric
06/24
09/24
KZR-261-101, NCT05047536: KZR-261 in Subjects With Advanced Solid Malignancies

Active, not recruiting
1
61
US
KZR-261, KZR-261 for Injection
Kezar Life Sciences, Inc.
Advanced/Metastatic Solid Tumor
12/25
12/26
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
Garcia-Tarodo, Stéphanie
NCT05017142: Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Recruiting
N/A
500
Europe
University of Bern, Schweizerische Multiple Sklerose Gesellschaft, Insel Gruppe AG, University Hospital Bern, Novartis, Anna Mueller Grocholski-Stiftung, Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel, Biogen, Roche Pharma (Switzerland) Ltd, Fondation Johanna Dürmüller-Bol, Kantonsspital Aarau, University Children's Hospital Basel, Ente Ospedaliero Cantonale, Bellinzona, Kantonsspital Graubünden, University Hospital, Geneva, Centre Hospitalier Universitaire Vaudois, Ostschweizer Kinderspital, Kantonsspital Winterthur KSW, Sanofi, Hôpital Fribourgeois, University Children's Hospital, Zurich, Luzerner Kantonsspital
Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Anti-NMDAR Encephalitis, Anti-GAD65 Associated Autoimmune Encephalitis, Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-Lgi-1 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephalitis, Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis, Hashimoto Encephalitis, CNS Vasculitis, CNS Sarcoidosis, CNS Lupus, Rasmussen Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
01/71
01/71
Labbaf, Layla
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
Kurian, Mary
NCT05017142: Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Recruiting
N/A
500
Europe
University of Bern, Schweizerische Multiple Sklerose Gesellschaft, Insel Gruppe AG, University Hospital Bern, Novartis, Anna Mueller Grocholski-Stiftung, Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel, Biogen, Roche Pharma (Switzerland) Ltd, Fondation Johanna Dürmüller-Bol, Kantonsspital Aarau, University Children's Hospital Basel, Ente Ospedaliero Cantonale, Bellinzona, Kantonsspital Graubünden, University Hospital, Geneva, Centre Hospitalier Universitaire Vaudois, Ostschweizer Kinderspital, Kantonsspital Winterthur KSW, Sanofi, Hôpital Fribourgeois, University Children's Hospital, Zurich, Luzerner Kantonsspital
Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Anti-NMDAR Encephalitis, Anti-GAD65 Associated Autoimmune Encephalitis, Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-Lgi-1 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephalitis, Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis, Hashimoto Encephalitis, CNS Vasculitis, CNS Sarcoidosis, CNS Lupus, Rasmussen Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
01/71
01/71

Download Options